Cizzle Biotechnology. 

€0.02
3
+€0+0% Today

Statistics

Day High
0.02
Day Low
0.02
52W High
0.02
52W Low
0.01
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

6MayExpected
Q2 2022
Q1 2024
Q1 2024
Q2 2024
Q1 2025
Q2 2025
Next
0
0.33
0.67
1
Expected EPS
N/A
Actual EPS
N/A

Financials

-Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
0Revenue
-2.58MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow E7F0.F. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
CRISPR Therapeutics
CRSP
Mkt Cap5.82B
CRISPR Therapeutics focuses on gene editing, competing in the innovative biotech space similar to Cizzle Biotechnology's focus on cancer diagnostics.
Editas Medicine
EDIT
Mkt Cap276.95M
Editas Medicine works on genome editing technology, directly competing in the biotechnology sector focusing on advanced therapies.
Intellia Therapeutics
NTLA
Mkt Cap1.35B
Intellia Therapeutics is a leader in CRISPR/Cas9 technology, a direct competitor in the genomic medicine field.
Alnylam Pharmaceuticals
ALNY
Mkt Cap60.25B
Alnylam Pharmaceuticals specializes in RNAi therapeutics, competing in the novel biopharmaceuticals market.
Sarepta Therapeutics
SRPT
Mkt Cap2.51B
Sarepta Therapeutics focuses on the discovery and development of RNA-targeted medicine, similar to Cizzle's innovative approach in biotechnology.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.29B
BioMarin Pharmaceutical develops and commercializes innovative biopharmaceuticals, competing in the same sector as Cizzle.
Vertex Pharmaceuticals
VRTX
Mkt Cap109.11B
Vertex Pharmaceuticals concentrates on creating new possibilities in medicine through scientific innovations, aligning with Cizzle's mission in biotech.
Regeneron Pharmaceuticals
REGN
Mkt Cap68.5B
Regeneron Pharmaceuticals is known for its scientific capabilities in biotechnology, making it a competitor in the field of medical biotech.
Sangamo Therapeutics
SGMO
Mkt Cap180.42M
Sangamo Therapeutics works on genomic medicine, including gene therapy, gene editing, and gene regulation, directly competing with Cizzle's biotechnological innovations.

About

Cizzle Biotechnology Holdings Plc, together with its subsidiaries, operates as a cancer diagnostics company in the United Kingdom. It develops a non-invasive blood test for early lung cancer detection using CIZ1B biomarker technology. The company was formerly known as Cizzle Biotechnology Limited and changed its name to Cizzle Biotechnology Holdings Plc in May 2021. Cizzle Biotechnology Holdings Plc is headquartered in London, the United Kingdom.
Show more...
CEO
Dr. Allan John Syms
Employees
4
Country
GB
ISIN
GB00BNG2VN02
WKN
000A3CPSF

Listings

0 Comments

Share your thoughts

FAQ

What is Cizzle Biotechnology. stock price today?
The current price of E7F0.F is €0.02 EUR — it has increased by +0% in the past 24 hours. Watch Cizzle Biotechnology. stock price performance more closely on the chart.
What is Cizzle Biotechnology. stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Cizzle Biotechnology. stocks are traded under the ticker E7F0.F.
When is the next Cizzle Biotechnology. earnings date?
Cizzle Biotechnology. is going to release the next earnings report on May 06, 2026.
What is Cizzle Biotechnology. revenue for the last year?
Cizzle Biotechnology. revenue for the last year amounts to 0 EUR.
What is Cizzle Biotechnology. net income for the last year?
E7F0.F net income for the last year is -2.58M EUR.
How many employees does Cizzle Biotechnology. have?
As of March 16, 2026, the company has 4 employees.
In which sector is Cizzle Biotechnology. located?
Cizzle Biotechnology. operates in the Health Care sector.
When did Cizzle Biotechnology. complete a stock split?
Cizzle Biotechnology. has not had any recent stock splits.
Where is Cizzle Biotechnology. headquartered?
Cizzle Biotechnology. is headquartered in London, GB.